Curis shares surged 70.7% in premarket trading, reaching $1.2188, amid heightened activity in the thinly traded biotech stock. The move came ahead of a shareholder vote on a proposed reverse stock split, scheduled for November 18 in a definitive proxy statement filed on November 2, 2026.
Curis’ board has described the split as a way to raise the share price above Nasdaq’s $1.00 minimum bid requirement and help avoid potential delisting. Shareholders had previously approved a split ratio ranging from 1-for-5 to 1-for-25 at a special meeting in June 2026, and the board is now proceeding toward a vote on the measure.
Investors are also awaiting initial data from the TakeAim CLL study, which is evaluating Curis’ lead candidate emavusertib with zanubrutinib in chronic lymphocytic leukemia. The first results are expected by the end of 2026, while a quarterly earnings report is anticipated within the next week. Curis’ low float can amplify share-price moves when buying interest increases.
The shares had already gained more than 15% in the previous session. While the reverse split vote, upcoming updates and limited float may have contributed to the premarket surge, no single disclosed event has been confirmed as its definitive trigger.
Sources: Investing.com News.